SCHEMBL1332877

SCHEMBL1332877

COc1nc(N[C@H]2CC[C@H](C)CC2)ncc1-c1ccc(SC)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.43
MAPK8 P45983 2/20 0.40
JUN P05412 2/20 0.39
MAPK10 P53779 2/20 0.39
ALDH1A1 P00352 1/20 0.37
ADORA1 P30542 3/20 0.36
ADORA2A P29274 2/20 0.36
ADORA2B P29275 1/20 0.36
FLT3 P36888 2/20 0.36
TYRO3 Q06418 2/20 0.36
MERTK Q12866 2/20 0.36
GAS6 Q14393 2/20 0.36
CDK1 P06493 4/20 0.36
CDK4 P11802 4/20 0.36
CCND1 P24385 3/20 0.36
CDK2 P24941 3/20 0.36
PDE10A Q9Y233 1/20 0.34
PCSK9 Q8NBP7 1/20 0.34
SYK P43405 1/20 0.34
PIK3CA P42336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1332875 1.00 GRM5 (0.43) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL3418538 0.83 GRM5 (0.43) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL3418540 0.83 GRM5 (0.43) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1034814 0.82 GRM5 (0.48) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1034813 0.82 GRM5 (0.48) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1334198 0.81 CDK4 (0.43) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1334197 0.81 CDK4 (0.43) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1334530 0.81 PDE10A (0.44) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1334531 0.81 PDE10A (0.44) GRM5MAPK8JUNMAPK10ALDH1A1
SCHEMBL1034545 0.81 PTGS1 (0.40) GRM5MAPK8JUNMAPK10FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS GRM5 2764/4885MAPK8 3599/4885JUN 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.